Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. (GBT) Revenue
Annual & quarterly revenue history · segment & region breakdown
GBT · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsGlobal Blood Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.23B, an increase of 57.31% year-over-year from $0.19B in FY2021.
Revenue trend
2021 – 2013 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2021-12-31 | $0.19B | +$0.07B | +57.31% |
| 2020-12-31 | $0.12B | +$0.12B | +5773.01% |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
| 2015-12-31 | $0.00B | +$0.00B | — |
| 2014-12-31 | $0.00B | +$0.00B | — |
| 2013-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare GBT revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Global Blood Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Global Blood Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Global Blood Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
GBT revenue · 4 questionsGBT's trailing twelve-month (TTM) revenue is $0.23B. That is an increase of 57.31% year-over-year from $0.19B in FY2021.
▸ Source: FMP · Global Blood Therapeutics, Inc. SEC filings · GAAP · Global Blood Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026